Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea Pharmaceutica (SIX: BSLN) records first commercial milestone payment from Japan
Published by Jyoti Prakash, CFA

Basilea Pharmaceutica has announced the receipt of its first commercial milestone payment of CHF1.2m from partner Asahi Kasei Pharma (AKP) for reaching an undisclosed sales threshold in Japan for its lead anti-infective drug Cresemba. Japan, along with China, are key new markets for Cresemba, making up c 25% of the drug’s global potential.  Cresemba recorded global in-market sales of US$533m in the 12-month period ending September 2024, at a 20% y-o-y growth rate. Importantly, unlike the US and European markets, where Cresemba is approaching maturity (market protection up to Q427), Japan is a fairly new entry for Cresemba (launched in January 2024, triggering a CHF5m development milestone from AKP), which comes with significantly longer exclusivity period and should support lifecycle management.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.